Pulmonx Corporation
NASDAQ:LUNGMedical - Devices
+$0.05 today
- Market cap
- $117.15M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$1.27
Volume 0.48M
Average 0.44M
LUNG Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Pulmonx CorporationNASDAQ: LUNG
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items growth accelerates
Q1 FY2026 other non-cash items of $4.82M rose 3946.2% year over year, ahead of the +832.9% change in trailing-twelve-month other non-cash items. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.
Context
- Other non-cash items amounted to 24.7% of revenue in FY2025, up 22.2 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3946.2% holds above the trailing-twelve-month pace of +832.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 22.33M USD
- Year-over-year change
- +957.2%
- 4-year CAGR
- +17.0%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.33M | +957.2% |
| FY2024 | 2024-12-31 | 2.11M | -1.4% |
| FY2023 | 2023-12-31 | 2.14M | -87.3% |
| FY2022 | 2022-12-31 | 16.8M | +41.0% |
| FY2021 | 2021-12-31 | 11.92M | — |
Other Non-Cash Items vs competitors
How LUNG compares with its peers on the latest reported figures
- LUNG's LTM Mar 2026 other non-cash items of $16.27M is the largest of the 10 companies compared; the peer median is $595K.
- Its year-over-year change of +832.9% is the highest of 10, against a peer median of +46.6%.
- Other non-cash items amounts to 18.4% of revenue for LUNG, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.27M | +832.9% | +9.9% | 18.4% | |
| LTM Mar 2026 | $13.87M | +24.4% | -13.1% | 13.6% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.27M | +14.2% | +214.5% | — |
| LTM Jun 2026 | $4.75M | +46.6% | -0.5% | 5.9% | |
| LTM Mar 2026 | $3.61M | +627.4% | — | — | |
| LTM Mar 2026 | $958K | +166.7% | — | 6.2% | |
| LTM Mar 2026 | $952K | -137.7% | -20.3% | 0.4% | |
| LTM Mar 2026 | $660K | -77.6% | — | 7.2% | |
| LTM Mar 2026 | $595K | +331.5% | -76.4% | — | |
| LTM Mar 2026 | $371K | +396.8% | — | — | |
| Peer median (excluding LUNG) | $595K | +46.6% | -13.1% | 6.2% | |
Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.66M) | (58.92M) | (60.84M) | (56.39M) | (54M) |
| Depreciation & Amortization | 3.16M | 4M | 1.55M | 1.49M | 1.15M |
| Deferred Income Tax | (6K) | 49K | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 22.1M | 22.96M | 0 |
| Change in Working Capital | (7.84M) | (7.06M) | (2.56M) | (1.7M) | (1.93M) |
| Accounts Receivables | (2.43M) | (2.19M) | (3.1M) | (1.31M) | 1.08M |
| Inventory | (6.46M) | (3.64M) | 918K | (229K) | (765K) |
| Accounts Payables | 87K | 247K | (345K) | 2.28M | 270K |
| Other Working Capital | 963K | (1.48M) | (27K) | (2.44M) | (2.51M) |
| Other Non-Cash Items | 11.92M | 16.8M | 2.14M | 2.11M | 22.33M |
| Operating Cash Flow | (41.43M) | (45.14M) | (37.61M) | (31.54M) | (32.45M) |
| Capital Expenditures | (3.67M) | (1.32M) | (807K) | (1.45M) | (452K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (52.58M) | (47.19M) | (46.2M) | (27.91M) | (5.65M) |
| Sales of Investments | 10M | 44.28M | 45M | 46.84M | 36.59M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (46.26M) | (4.23M) | (2.01M) | 17.48M | 30.48M |
| Debt Repayment | 0 | (87K) | 19.91M | (95K) | (100K) |
| Common Stock Issued | 4.52M | 2.59M | 0 | 0 | 1M |
| Common Stock Repurchased | (26K) | (27K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1.49M | 1.46M | 0 |
| Financing Cash Flow | 4.5M | 2.47M | 21.4M | 1.36M | 903K |
| Effect of Forex Changes | 106K | 145K | 34K | 76K | (92K) |
| Net Change in Cash | (83.08M) | (46.74M) | (18.18M) | (12.62M) | (1.15M) |
| Free Cash Flow | (45.1M) | (46.45M) | (38.42M) | (32.98M) | (32.9M) |
Pulmonx Corporation
NASDAQ:LUNG
Intrinsic Alpha fair value
Locked
Current Price
$2.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.